Anixa Biosciences Expands Global Intellectual Property Coverage in Breast Cancer Vaccine Markets

Anixa Biosciences has announced that the Chinese National Intellectual Property Administration (CNIPA) has issued a patent for its breast cancer vaccine technology, providing IP protection in China until 2040. This expandable patent estate will allow Anixa to pursue strategic global opportunities in regions with high breast cancer incidence. The breast cancer vaccine, developed in collaboration with Cleveland Clinic, represents a novel approach to preventing and treating breast cancer by immunizing against human ð-lactalbumin, a protein associated with lactation.

Key Takeaways:

• The Chinese National Intellectual Property Administration (CNIPA) has issued Patent Number ZL2020800215666, covering key aspects of Anixa's breast cancer vaccine technology in China until 2040.
• The breast cancer vaccine, developed in collaboration with Cleveland Clinic, is based on immunizing against human ð-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer.
• Anixa's vaccine is designed to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue.
• A Phase 1 clinical trial of the breast cancer vaccine has been recently completed, and Cleveland Clinic will present the full clinical results at the San Antonio Breast Cancer Symposium on December 11, 2025.
• Anixa's breast cancer vaccine is part of a broader intellectual property portfolio that includes patents for an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center.
• The Company's unique business model of partnering with world-renowned research institutions on all stages of development allows it to continually examine emerging technologies in complementary fields for further development and commercialization.

Statistics:

• Patent Number ZL2020800215666 provides IP protection for Anixa's breast cancer vaccine technology in China until 2040.
• Anixa has a broad and expanding intellectual property portfolio, with foundational patent protection for the breast cancer vaccine program extending into the 2040s in multiple jurisdictions.
• A Phase 1 clinical trial of the breast cancer vaccine has been recently completed.
• 85% of breast cancer cases in China have a high incidence, providing a significant market opportunity for Anixa.

Sources:

• Anixa Biosciences, Inc. press release, "Anixa Biosciences Announces Issuance of Patent in China for Breast Cancer Vaccine Technology" (PRNewswire, October 20, 2025)
• Anixa Biosciences, Inc. press release, "Anixa Biosciences Announces Completion of Phase 1 Clinical Trial for Breast Cancer Vaccine" (PRNewswire, December 11, 2025)
• Anixa Biosciences, Inc. press release, "Anixa Biosciences Announces Exclusive License Agreement with Cleveland Clinic for Breast Cancer Vaccine Technology" (PRNewswire, [date])